11 Best Growth Stocks to Buy and Hold Forever

Core Viewpoint - The article discusses the best growth stocks to buy and hold for the long term, highlighting a positive outlook for equity markets amid a resilient US economy and low-interest-rate environment [1][4]. Group 1: Market Outlook - Global equities are expected to continue rising despite valuation concerns, with a Bank of America survey indicating that most fund managers remain overweight in equities [1][2]. - The risk of a recessionary trade war is diminishing, contributing to a bullish sentiment in equity markets [2]. - The US Federal Reserve's hints at potential interest rate cuts further enhance the outlook for growth stocks, which typically trade at a premium [2][3]. Group 2: Methodology for Stock Selection - The selection of the best growth stocks involved using the Finviz screener to identify stocks with over 10% EPS growth in the past five years and an expected EPS growth rate of at least 20% over the next five years [6]. - The list was narrowed to stocks with a forward price-to-earnings ratio exceeding 20 and popularity among elite hedge funds in Q2 2025 [6][7]. Group 3: Featured Growth Stocks - Comfort Systems USA, Inc. (NYSE:FIX): - EPS Growth Over the Past Five Years: 36.52% - EPS Growth Over the Next Five Years: 24.58% - Forward Price to Earnings Ratio: 30.31 - Number of Hedge Fund Holders: 53 - UBS raised its price target to $875, citing strong financial health and a robust project environment [8][9][10]. - Howmet Aerospace Inc. (NYSE:HWM): - EPS Growth Over the Past Five Years: 22.24% - EPS Growth Over the Next Five Years: 23.36% - Forward Price to Earnings Ratio: 44 - Number of Hedge Fund Holders: 57 - The company is experiencing healthy growth in its spares business and is investing in capacity expansion to meet demand [12][13][14][15]. - DexCom, Inc. (NASDAQ:DXCM): - EPS Growth Over the Past Five Years: 39.06% - EPS Growth Over the Next Five Years: 24.59% - Forward Price to Earnings Ratio: 26.07 - Number of Hedge Fund Holders: 60 - UBS maintains a bullish stance on the company despite concerns over its G7 continuous glucose monitoring sensor, expecting strong demand for CGM technology [16][17][18][19].